<?xml version="1.0" encoding="UTF-8"?>
<p>At present, Hepatitis B Virus (HBV) infection is an important public health problem worldwide. Hepatitis B can lead to serious liver diseases, including cirrhosis, liver cancer. In China, approximately 120 million people are infected with the Hepatitis B Virus (
 <xref rid="A29052R1" ref-type="bibr">1</xref>). Alavian et al. reported that about 1 million people are infected with HBV in Iran, and 15% to 40% of the patients with hepatitis B may develop cirrhosis or liver cancer (
 <xref rid="A29052R2" ref-type="bibr">2</xref>). Liver fibrosis is a healing response, but the excessive accumulation of extracellular matrix (ECM) components in the liver often leads to severe forms of liver fibrosis, and ultimately cirrhosis with liver dysfunction (
 <xref rid="A29052R3" ref-type="bibr">3</xref>-
 <xref rid="A29052R5" ref-type="bibr">5</xref>). Early cirrhosis may be reversible. Therefore, prompt diagnosis and intervention are critical in limiting disease progression (
 <xref rid="A29052R6" ref-type="bibr">6</xref>). Clinically, the existing hepatoprotective agents include Ursodesoxycholic acid (UDCA), silibinin, and N-acetylcysteine (NAC).
</p>
